|Bid||0.0750 x 0|
|Ask||0.0800 x 0|
|Day's Range||0.0700 - 0.0750|
|52 Week Range||0.0600 - 0.3200|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||0.16|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul. 21, 2005|
|1y Target Est||N/A|
OncoQuest Pharmaceuticals Inc., ("OncoQuest") a clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer, today announces the first patient enrolled in each of two investigator initiated clinical trials assessing the safety and efficacy of oregovomab in a previously treated recurrent ovarian cancer setting.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company") today announced the results of its July 5, 2021 annual general and special meeting of shareholders.
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") announces that clinical investigators working with OncoQuest Pharmaceuticals, Inc. ("OQP") lead clinical candidate oregovomab, will be making two presentations as part of the American Society of Clinical Oncology (ASCO) conference proceedings. OQP acquired oregovomab from OncoQuest Inc., one of the equity investee companies (45%) of Quest PharmaTech Inc.